These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 37355297

  • 1. [Classical nephroprotection: Renin angiotensin aldosterone system inhibitors].
    Egocheaga MI, Drak Y, Otero V.
    Semergen; 2023 Jun; 49 Suppl 1():102018. PubMed ID: 37355297
    [Abstract] [Full Text] [Related]

  • 2. Renin-angiotensin-aldosterone system blockers effect in chronic kidney disease progression in hypertensive elderly patients without proteinuria: PROERCAN trial.
    García-Prieto AM, Verdalles Ú, de José AP, Arroyo D, Aragoncillo I, Barbieri D, Camacho RE, Goicoechea M.
    Hipertens Riesgo Vasc; 2024 Jun; 41(2):95-103. PubMed ID: 38508877
    [Abstract] [Full Text] [Related]

  • 3. Can patiromer allow for intensified renin-angiotensin-aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD.
    Mårup FH, Peters CD, Christensen JH, Birn H.
    BMJ Open; 2022 Feb 21; 12(2):e057503. PubMed ID: 35190442
    [Abstract] [Full Text] [Related]

  • 4. Mineralcorticoid receptor blockers in chronic kidney disease.
    Erraez S, López-Mesa M, Gómez-Fernández P.
    Nefrologia (Engl Ed); 2021 Feb 21; 41(3):258-275. PubMed ID: 36166243
    [Abstract] [Full Text] [Related]

  • 5. The renin-angiotensin-aldosterone system blockade in patients with advanced diabetic kidney disease.
    Bermejo S, García CO, Rodríguez E, Barrios C, Otero S, Mojal S, Pascual J, Soler MJ.
    Nefrologia (Engl Ed); 2018 Feb 21; 38(2):197-206. PubMed ID: 29102270
    [Abstract] [Full Text] [Related]

  • 6. Use of renin-angiotensin-aldosterone system blockade in controversial chronic kidney disease populations.
    García-Prieto AM, Verdalles Ú, Goicoechea M.
    Med Clin (Barc); 2021 Jun 11; 156(11):561-567. PubMed ID: 33757646
    [Abstract] [Full Text] [Related]

  • 7. The effect of renin-angiotensin-aldosterone system blockers on the progression of chronic kidney disease in hypertensive elderly patients without proteinuria: PROERCAN study. Rationale and design.
    García-Prieto AM, Verdalles Ú, de José AP, Verde E, Arroyo D, Aragoncillo I, Linares T, Barbieri D, Goicoechea M.
    Hipertens Riesgo Vasc; 2020 Jun 11; 37(3):101-107. PubMed ID: 32156479
    [Abstract] [Full Text] [Related]

  • 8. Detrimental effect of renin-angiotensin blockade on progression of chronic kidney disease at later stages: A matter of dosage adjustment?
    Caravaca-Fontán F, Valladares J, Díaz-Campillejo R, Barroso S, Luna E, Caravaca F.
    Nefrologia (Engl Ed); 2020 Jun 11; 40(1):38-45. PubMed ID: 31196659
    [Abstract] [Full Text] [Related]

  • 9. The Use of Renin-Angiotensin System Inhibitors in Patients With Chronic Kidney Disease.
    Leon SJ, Tangri N.
    Can J Cardiol; 2019 Sep 11; 35(9):1220-1227. PubMed ID: 31472818
    [Abstract] [Full Text] [Related]

  • 10. Therapeutic approaches in lowering albuminuria: travels along the renin-angiotensin-aldosterone-system pathway.
    Heerspink HJ.
    Adv Chronic Kidney Dis; 2011 Jul 11; 18(4):290-9. PubMed ID: 21782135
    [Abstract] [Full Text] [Related]

  • 11. [Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)].
    Santoro A, Mandreoli M.
    G Ital Nefrol; 2018 May 11; 35(3):. PubMed ID: 29786183
    [Abstract] [Full Text] [Related]

  • 12. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
    Werner C, Pöss J, Böhm M.
    Drugs; 2010 Jul 09; 70(10):1215-30. PubMed ID: 20568830
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis.
    Susantitaphong P, Sewaralthahab K, Balk EM, Eiam-ong S, Madias NE, Jaber BL.
    Am J Hypertens; 2013 Mar 09; 26(3):424-41. PubMed ID: 23382494
    [Abstract] [Full Text] [Related]

  • 14. An Overview of Clinically Imperative and Pharmacodynamically Significant Drug Interactions of Renin-Angiotensin-Aldosterone System (RAAS) Blockers.
    Mohamed Pakkir Maideen N, Balasubramanian R, Muthusamy S, Nallasamy V.
    Curr Cardiol Rev; 2022 Mar 09; 18(6):e110522204611. PubMed ID: 35546745
    [Abstract] [Full Text] [Related]

  • 15. Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease.
    Komers R, Plotkin H.
    Am J Physiol Regul Integr Comp Physiol; 2016 May 15; 310(10):R877-84. PubMed ID: 27009050
    [Abstract] [Full Text] [Related]

  • 16. Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation?
    Sarafidis PA, Ruilope LM.
    Kidney Int; 2014 Mar 15; 85(3):536-46. PubMed ID: 24048382
    [Abstract] [Full Text] [Related]

  • 17. Renin-angiotensin-aldosterone system inhibition: overview of the therapeutic use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, and direct renin inhibitors.
    Mercier K, Smith H, Biederman J.
    Prim Care; 2014 Dec 15; 41(4):765-78. PubMed ID: 25439533
    [Abstract] [Full Text] [Related]

  • 18. Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease.
    Yamout H, Lazich I, Bakris GL.
    Adv Chronic Kidney Dis; 2014 May 15; 21(3):281-6. PubMed ID: 24780456
    [Abstract] [Full Text] [Related]

  • 19. Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria.
    Morales E, Gutiérrez E, Caro J, Sevillano A, Rojas-Rivera J, Praga M.
    Nefrologia; 2015 May 15; 35(6):554-61. PubMed ID: 26519114
    [Abstract] [Full Text] [Related]

  • 20. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
    Cestário EDES, Fernandes LAB, Giollo-Júnior LT, Uyemura JRR, Matarucco CSS, Landim MIP, Cosenso-Martin LN, Tácito LHB, Moreno H, Vilela-Martin JF, Yugar-Toledo JC.
    Trials; 2018 Feb 12; 19(1):101. PubMed ID: 29433578
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.